American Journal of Cardiology
Volume 97, Issue 8, Supplement 1 , Pages S61-S68 , 17 April 2006

Statin Safety: An Assessment Using an Administrative Claims Database

  • Mark J. Cziraky, PharmD

      Affiliations

    • HealthCore, Inc., Wilmington, Delaware, USA
    • Corresponding Author InformationAddress for reprints: Mark J. Cziraky, PharmD, HealthCore, Inc., 800 Delaware Avenue, 5th Floor, Wilmington, Delaware 19801
    • ,
  • Vincent J. Willey, PharmD

      Affiliations

    • HealthCore, Inc., Wilmington, Delaware, USA
    • ,
  • James M. McKenney, PharmD

      Affiliations

    • National Clinical Research, Inc., Richmond, Virginia, USA
    • ,
  • Siddhesh A. Kamat, MS

      Affiliations

    • HealthCore, Inc., Wilmington, Delaware, USA
    • ,
  • Maxine D. Fisher, PhD

      Affiliations

    • HealthCore, Inc., Wilmington, Delaware, USA
    • ,
  • John R. Guyton, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina, USA
    • ,
  • Terry A. Jacobson, MD

      Affiliations

    • Emory University, Atlanta, Georgia, USA
    • ,
  • Michael H. Davidson, MD

      Affiliations

    • Rush University Medical Center, Chicago, Illinois, USA

References 

  1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report . Circulation . 2002;106:3143–3421
  2. Davidson MH . Safety profiles for the HMG-CoA reductase inhibitors (treatment and trust) . Drugs . 2001;61:197–206
  3. Evans M , Rees A . The myotoxicity of statins . Curr Opin Lipidol . 2002;13:415–420
  4. Tomlinson B , Chan P , Lan W . How well tolerated are lipid-lowering drugs? . Drugs Aging . 2001;18:665–683
  5. Wortmann RL . Lipid-lowering agents and myopathy . Curr Opin Rheumatol . 2002;14:643–647
  6. Furberg CD , Pitt B . Withdrawal of cerivastatin from the world market . Curr Control Trials Cardiovasc Med . 2001;2:205–207
  7. Fontanarosa PB , Rennie D , DeAngelis CD . Postmarketing surveillance—lack of vigilance, lack of trust . JAMA . 2004;292:2647–2650
  8. Andrade SE, Graham DJ, Staffa JA, Scheck SD, Shatin D, La Grenade L Goodman MJ, et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis . J Clin Epidemiol . 2005;58:171–174
  9. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs . JAMA . 2004;292:2585–2590
  10. Ernster VL . Nested case-control studies . Prev Med . 1994;23:587–590
  11. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs (nested case-control study) . Lancet . 2005;365:475–481
  12. Pang D . A relative power table for nested matched case-control studies . Occup Environ Med . 1999;56:67–69
  13. Staffa JA , Chang J , Green L . Cerivastatin and reports of fatal rhabdomyolysis . N Engl J Med . 2002;346:539–540
  14. Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C, et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting . Circulation . 2005;111:488–493
  15. Zielinski SL . FDA attempting to overcome major roadblocks in monitoring drug safety . J Natl Cancer Inst . 2005;97:872–873
  16. Cottrell DA , Marshall BJ , Falko JM . Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome . Curr Opin Cardiol . 2003;18:301–308
  17. Thummel KE , Wilkinson GR . In vitro and in vivo drug interactions involving human CYP3A . Annu Rev Pharmacol Toxicol . 1998;38:389–430
  18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian Simvastatin Survival Study (4S)) . Lancet . 1994;344:1383–1389
  19. Collins R , Armitage J , Parish S , Sleigh P , Peto R  Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes (a randomised placebo-controlled trial) . Lancet . 2003;361:2005–2016
  20. Alsheikh-Ali AA , Ambrose MS , Kuvin JT , Karas RH . The safety of rosuvastatin as used in common clinical practice (a postmarketing analysis) . Circulation . 2005;111:3051–3057
  21. Cheung BM , Lauder IJ , Lau CP , Kumana CR . Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes . Br J Clin Pharmacol . 2004;57:640–651
  22. Omar MA , Wilson JP . FDA adverse event reports on statin-associated rhabdomyolysis . Ann Pharmacother . 2002;36:288–295
  23. Ford ES , Giles WH , Dietz WH . Prevalence of the metabolic syndrome among US adults (findings from the third National Health and Nutrition Examination Survey) . JAMA . 2002;287:356–359

PII: S0002-9149(05)02144-2

doi: 10.1016/j.amjcard.2005.12.011

American Journal of Cardiology
Volume 97, Issue 8, Supplement 1 , Pages S61-S68 , 17 April 2006

Article Tools

* Image Usage & Resolution